Teva says I deu

The latest deal by Teva Pharmaceutical Industries Ltd. suggests the company has not changed course under new leadership, at least when it comes to building its CNS pipeline via business development. Last week, Teva said it would acquire deuteration play Auspex Pharmaceuticals Inc. for $3.5 billion in cash to get Austedo deutetrabenazine and a portfolio of more than 60 IP-protected candidate molecules.

Austedo is in development for movement disorders with no or few treatments available. The most advanced indication is chorea associated with Huntington's disease (HD). Auspex expects to submit an NDA for the indication in mid-2015. ...